H.C. Wainwright initiated coverage of Jasper Therapeutics with a Buy rating and $65 price target. The company’s pipeline consists of IV and subcutaneous formulations for its lead asset, briquilimab, which is an anti-c-Kit monoclonal antibody in development for mast cell driven disease and stem cell driven diseases, the analyst tells investors in a research note. The firm believes briquilimab represents a pipeline within a product.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- TipRanks ‘Perfect 10’ List: These 2 Top-Scoring Stocks Could Double (or More), According to Analysts
- Jasper Therapeutics initiated with an Outperform at Evercore ISI
- Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Jasper Therapeutics initiated with an Outperform at RBC Capital
- Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference